tbuckley/cabot-search huggingface dataset:
Voruciclib Sensitizes High Risk Diffuse Large B Cell Lymphoma to BCL2 Inhibition Mediated Cell Death and Tumor Regression
Authors: Joyoti Dey, William Kerwin, Joseph Casalini, Angela Merrell, Marc Grenley, Sally Ditzler, Chantel Dixon, Connor Burns, Alexey V Danilov, Richard Klinghoffer
Journal: Blood (2016)
The Use of Tri-Ponderal Mass Index and Other Indices in Estimating Visceral Body Fat Percentages in Adolescents—Reply
Authors: Courtney M. Peterson, Diana M. Thomas, Steven B. Heymsfield
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Initial results of a phase 1 dose expansion cohort of M6620 (formerly VX-970), an ATR inhibitor, in combination with cisplatin in patients with advanced triple-negative breast cancer NCT02157792)
Authors: M.L. Telli, S. Lord, E. Dean, V. Abramson, H-T. Arkenau, C. Becerra, S.M. Tolaney, R. Tang, M.S. Penney, J. Pollard, G. Conboy, S.Z. Fields, G. Shapiro
Journal: Annals of Oncology (2017)
Seroprevalencia de los anticuerpos frente al virus de la poliomielitis en habitantes de Portugal, 2002
Authors: Marta Pires de Miranda, M Carmo Gomes, H Rebelo de Andrade
Journal: Eurosurveillance (2007)

El ultimo caso de poliomielitis causado por el poliovirus salvaje autoctono en Portugal se registro en 1986, y en 2002 se declaro a la poliomielitis erradicada en el pais.
Vigilância da tuberculose na Europa
Authors: V Schwoebel, H. L. Rieder, J M Watson, M. C. Raviglione
Journal: Eurosurveillance (1996)

O indicador de morbilidade por tuberculose mais prontamente acessivel e informativo e o de incidencia da doenca. Na Europa, diferencas entre paises na definicao de caso, sistemas de notificacao e recolha de informacao dificultam comparacoes e comprometem a analise de tendencias temporais, a identificacao de grupos populacionais comuns, entre os quais a incidencia e elevada e a coordenacao internacional de esforcos para controlo da tuberculose na Europa.
Frequent ERBB3 (HER3) activating mutations in small bowel adenocarcinomas
Authors: L. Cabel, I. Bieche, T. Aparicio, M. Svrcek, A. Zaanan, P. Afchain, F. Di Fiore, J-M. Gornet, D. Le Corre, S. Vacher, C. Callens, V. Bernard, P. Laurent-Puig, F-C. Bidard
Journal: Annals of Oncology (2017)
Blunders will never cease
Authors: Trevor Jackson, Alison Harper
Journal: BMJ (2001)

# How the media report medical errors {#article-title-2}

On the front page of London's Evening Standard of 14 February the face of 3 year old Najiyah Hussain, beside the headline “She was killed by a hospital,” looks the epitome of wronged innocence. The paper's principal focus is the human tragedy of Najiyah and of her family. There has been little time, and little space, for analysis. But we are told: “Police are investigating the incident and a doctor has been suspended.”

The facts seem obvious. Najiyah, “given laughing gas instead of oxygen,” was the victim of a mistake that you would not expect could happen in a modern health service. A victim, just like Wayne Jowett, who died on 2 February, a month after vincristine was injected into his spine instead of a vein at Queen's Medical Centre, Nottingham. And just like the 74 year old man who died at the Royal Sussex County Hospital, Brighton, after the wrong drug was administered during surgery on 7 February.

Yet mistakes of the kind that led to such deaths are not as …
Trasmisión inter-humana del virus A/H7N7 de la gripe aviar, Países Bajos, 2003
Authors: M Du Ry van Beest Holle, A Meijer, M Koopmans, C M de Jager
Journal: Eurosurveillance (2005)

En los Paises Bajos en 2003, se declaro en granjas de aves un brote de virus de gripe aviar muy patogeno de tipo A y subtipo H7N7. La infeccion por el virus se detecto por RT-PCR (reverse transcriptase-polymerase chain reaction) en 86 trabajadores de granjas y en tres contactos familiares. La mayoria de las infecciones estaba asociada con una conjuntivitis. Para determinar la amplitud y los factores de riesgo para la trasmision interhumana de gripe A/H7N7 en los Paises Bajos, se llevo a cabo un estudio de cohorte retrospectivo en las familias de los empleados de la granja infectados por el virus. En total, 33 (58,9%) de los 56 (entre 62) participantes que habian dado muestras de sangre tenian una serologia positiva para el virus H7. Las pruebas se realizaron en una sola muestra obtenida al menos tres semanas despues del inicio de sintomas en el caso indice. Ocho miembros familiares (12,9%) tuvieron sintomas (conjuntivitis y/o sindrome gripal), de los cuales cuatro (80%) de los cinco que tenian muestras de sangre fueron seropositivos. En los analisis univariados, los factores de riesgo para seropositividad incluian tener al menos dos banos, un pajaro en la casa, y usar panuelos de tela. Resulto imposible obtener un modelo estable de regresion binomial para estudiar la infeccion por A/H7N7. Deberian llevarse a cabo mas estudios de seroprevalencia en los contactos de casos H7 asintomaticos.
Thromboembolic complications in patients with oesophagogastric adenocarcinoma undergoing preoperative chemotherapy
Authors: T. Germetaki, K. Kamposioras, G. Papaxoinis, J. Weaver, S. Galloway, S. Stamatopoulou, M. Nasralla, Z. Kordatou, A. Anthoney, W. Mansoor
Journal: Annals of Oncology (2017)
Effect of bisphosphonates on knee replacement surgery
Authors: Tuhina Neogi, Shanshan Li, Christine Peloquin, Devyani Misra, Yuqing Zhang
Journal: Annals of the Rheumatic Diseases (2017)

Bone remodelling as a therapeutic target in knee osteoarthritis (OA) has gained much interest, but the effects of antiresorptive agents on knee OA have been conflicting, with no studies to date examining the effects of bisphosphonate use on the clinically relevant endpoint of knee replacement (KR) surgery.We used data from The Health Improvement Network (THIN), a general practitioner electronic medical records representative of the general UK population. We identified older women who had initiated bisphosphonate use after their incident knee OA diagnosis. Each bisphosphonate initiator was propensity score-matched with a non-initiator within each 1-year cohort accrual block. The effect of bisphosphonates on the risk of KR was assessed using Cox proportional hazard regression. Sensitivity analyses to address residual confounding were also conducted.We identified 2006 bisphosphonate initiators, who were matched to 2006 non-initiators(mean age 76, mean body mass index 27), with mean follow-up time of 3 years. The crude incidence rate of KR was 22.0 per 1000 person-years among the initiators, and 29.1 among the non-initiators. Bisphosphonate initiators had 26% lower risk of KR than non-initiators(HR 0.74, 95% CI 0.59 to 0.93); these results were similar when additionally adjusted for potential confounders in the propensity score (HR 0.76, 95% CI 0.60 to 0.95). Results of sensitivity analyses supported this protective effect.In this population-based cohort of older women with incident knee OA, those with incident bisphosphonate users had lower risk of KR than non-users of bisphosphonates, suggesting a potential beneficial effect of bisphosphonates on knee OA.
Selective Internal Radiation Therapy (SIRT) with Yttrium-90-glass-microspheres plus chemotherapy in first-line treatment of advanced cholangiocarcinoma (MISPHEC study)
Authors: J. Edeline, Y. Touchefeu, B. Guiu, O. Farges, D. Tougeron, P. Compagnon, L. Chone, B. Campillo-Gimenez, M. Pracht, A. Lievre, S. Le Sourd, K. Boudjema, E. Garin, E. Boucher
Journal: Annals of Oncology (2017)
Abstract 12989: Attenuation of Renal Fibrosis and Inflammation in Npr1 Haplotype Mice by Retinoic Acid and Sodium Butyrate via Interactive Modulation of STAT1, HDACs and NF-κB
Authors: Prerna Kumar, Ramu Periyasamy, Venkateswara R Gogulamudi, Kailash N Pandey
Journal: Circulation (2016)

Introduction: Mice lacking functional guanylyl cyclase/natriuretic peptide receptor-A (GC-A/NPRA) gene (Npr1) exhibit hypertension, kidney disease, and heart failure. In this study, we investigated...
Current Shortcomings of Camera Screening—Reply
Authors: Lauren P. Daskivich, Carol M. Mangione
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
High precompetition injury rate dominates the injury profile at the Rio 2016 Summer Paralympic Games: a prospective cohort study of 51 198 athlete days
Authors: Wayne Derman, Phoebe Runciman, Martin Schwellnus, Esme Jordaan, Cheri Blauwet, Nick Webborn, Jan Lexell, Peter van de Vliet, Yetsa Tuakli-Wosornu, James Kissick, Jaap Stomphorst
Journal: British Journal of Sports Medicine (2017)

To describe the incidence of injury in the precompetition and competition periods of the Rio 2016 Summer Paralympic Games.A total of 3657 athletes from 78 countries, representing 83.4% of all athletes at the Games, were monitored on the web-based injury and illness surveillance system over 51 198 athlete days during the Rio 2016 Summer Paralympic Games. Injury data were obtained daily from teams with their own medical support.A total of 510 injuries were reported during the 14-day Games period, with an injury incidence rate (IR) of 10.0 injuries per 1000 athlete days (12.1% of all athletes surveyed). The highest IRs were reported for football 5-a-side (22.5), judo (15.5) and football 7-a-side (15.3) compared with other sports (p<0.05). Precompetition injuries were significantly higher than in the competition period (risk ratio: 1.40, p<0.05), and acute traumatic injuries were the most common injuries at the Games (IR of 5.5). The shoulder was the most common anatomical area affected by injury (IR of 1.8).The data from this study indicate that (1) IRs were lower than those reported for the London 2012 Summer Paralympic Games, (2) the sports of football 5-a-side, judo and football 7-a-side were independent risk factors for injury, (3) precompetition injuries had a higher IR than competition period injuries, (4) injuries to the shoulder were the most common. These results would allow for comparative data to be collected at future editions of the Games and can be used to inform injury prevention programmes.
Initial experience of radium-223 treatment for metastatic castrate resistant prostate cancer in community setting.
Authors: Christopher Michael Pieczonka, Marc Nicolas Bienz, Vladimira Mouravieva, David Albala, Vladimir Mouraviev, Neil Mariados
Journal: Journal of Clinical Oncology (2014)

e16106 Background: The many advantages associated with Ra-223 cytotoxic mechanism of action and excretion makes it a stronger, less myelotoxic and nephrotoxic option than its counterparts (Sm153 and Sr89). We report the shortterm pain evolution, side effects and hematologic profile of patients with metastatic castrate-resistant prostate cancer (mCRPC) undergoing Ra-223 treatment. Methods: Clinical data from 19 mCRPC patients treated with Ra-223 was collected from a large multi-disciplinary group. In accordance with the FDA’s recommended dosage, Ra-223’s monthly injections were composed of 1 dose of 50 kBq/kg, for 6 months. Up to the third injection, the World Health Organization’s (WHO) ladder for cancer pain was assessed and the pain pattern evaluated and classified in groups: no or minimal pain relief, worsening and improvement of pain. Also, short-term incidence of side effects was reported together with the hematologic parameters at each injection. Data is expressed as a median (range). Results: This cohort was composed of 19 Caucasian men aged 74 (53-85) years old, and all suffered bone metastasis. At baseline, 13.3% graded the pain at 1 according to the WHO pain score. At the first follow-up, 27 (19-35) days after the first injection, 21.5% (2/19) noticed pain relief, and 37.5% had a WHO score of 1. 22 (21-22) days after the second injection, 44.4% (8/18) had reduced pain symptoms, and 37.5% had a WHO score of 1. At the third follow-up, 35 (22-35) days after the third injection, 50% (6/12) had pain relief, and 50% had a WHO score of 1. Also, for 10.5% (n=2) of our cohort, pain symptoms worsened while 21% (n=4) reached total pain remission by the third injection. Increased bowl movement frequency was observed in 10.5% of our cohort, diarrhea in 31.6%, constipation in 5.3%, nausea in 26.3%, vomiting in 5.3%, bone pain flair response in 26.3% and lower limb edema in 10.5%. Conclusions: Our short-term results demonstrated promising bone-pain relief effect of Ra-223 in 50% of our patients even after a maximum of only three injections. Encountered side effects were mild including mostly gastro-intestinal symptoms, but a 21.3% platelet reduction was observed by the third injection.
Encouraging activity of novel pan-KIT and PDGFRα inhibitor DCC-2618 in patients (pts) with Gastrointestinal Stromal Tumor (GIST)
Authors: F. Janku, A.R.A. Razak, M.S. Gordon, D. Flynn, M. Kaufman, J. Pitman, B. Smith, N. Somaiah, J. Jennings, S. Salah, D. Westwood, D. Greensmith, J. Jacobson, O. Rosen, S. George
Journal: Annals of Oncology (2017)
Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers
Authors: Silvia Cantoni, Monica Carpenedo, Maria Gabriella Mazzucconi, Valerio De Stefano, Valentina Carrai, Marco Ruggeri, Giorgina Specchia, Nicola Vianelli, Fabrizio Pane, Ugo Consoli, Andrea Artoni, Francesco Zaja, Mariella D'adda, Andrea Visentin, Felicetto Ferrara, Wilma Barcellini, Domenica Caramazza, Erminia Baldacci, Elena Rossi, Alessandra Ricco, Angela Ciminello, Francesco Rodeghiero, Michele Nichelatti, Roberto Cairoli
Journal: American Journal of Hematology (2017)

Sequential use of the TPO-RAs romiplostim and eltrombopag in ITP patients failing either agent was retrospectively evaluated to assess efficacy and impact of clinical characteristics on outcome. Patients were grouped into 5 categories: efficacy issues: 1st TPO-RA failure; loss of response; non-efficacy issues: platelet fluctuations; patient's preference; adverse event development. Either one TPO-RA sequence was analyzed at 3 month and at last follow-up. 106/546 patients on TPO-RA underwent switch and 65% achieved, regained or maintained a short- term response independent of switch sequence, gender or age; lower response rates were associated with lines of previous therapy; disease duration lowers probability to respond. Clinically, patients switched for efficacy issue did not differ from those switched for non-efficacy issues. Response was achieved/regained in 57.8% of patients switched for efficacy issues, the lowest response rates were observed in non-responders to 1st TPO-RA; 80% of patients switched for non-efficacy issues maintained a response. Platelet fluctuation resolved in 44.4%. Of the 49 patients evaluable for long-term outcome, 27 were in response on therapy; 16 discontinued the TPO-RA for reasons other than efficacy, while only 6 were non responders. We confirm the efficacy of TPO-RA switch; once achieved, response to the 2nd TPO-RA seems durable.
SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (with or without letrozole in ER+) in previously trastuzumab-pretreated, postmenopausal patients with HER2-positive metastatic breast cancer
Authors: P. Villagrasa Gonzalez, A. Prat, M. Oliveira, L. de la Pena, X. Gonzalez, J. Cortes Castan, J. Rios, J. Vázquez, N. Martínez Jañez, A. Perelló Martorell, I. Garau, E. Martinez de Dueñas, S. Morales, M. Melé, B. Bermejo De Las Heras, E. Ciruelos
Journal: Annals of Oncology (2017)
GW28-e0699 Cardiovascular risk stratification and gender differences in hypertensive patients with metabolic syndrome
Authors: Alyavi Anis Lutfullayevich, Alyavi Baxrom Anisxonovich, Uzokov Jamol Kamilovich, Azizov Shuxrat Ismatovich, Kayumov Nodir Ulugbekovich
Journal: Journal of the American College of Cardiology (2017)
Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer
Authors: Laura Spring, Rachel Greenup, Andrzej Niemierko, Lidia Schapira, Stephanie Haddad, Rachel Jimenez, Suzanne Coopey, Alphonse Taghian, Kevin S. Hughes, Steven J. Isakoff, Leif W. Ellisen, Barbara L. Smith, Michelle Specht, Beverly Moy, Aditya Bardia
Journal: Journal of the National Comprehensive Cancer Network (2017)

Purpose: Breast cancer in young women is associated with an aggressive tumor biology and higher risk of recurrence. Pathologic complete response (pCR) after neoadjuvant therapy has been shown to be a surrogate marker for disease-free survival (DFS) and overall survival (OS), but the association between pCR and survival outcomes in young women with breast cancer is not well described. Methods: This study included women aged ≤40 years at diagnosis who received neoadjuvant chemotherapy (NAC) for stage II–III invasive breast cancer between 1998 and 2014 at Massachusetts General Hospital. Outcomes were compared between patients who achieved pCR (ypT0/is, ypN0) and those with residual disease. Results: A total of 170 young women were included in the analytical data set, of which 53 (31.2%) achieved pCR after NAC. The 5-year DFS rate for patients with and without pCR was 91% versus 60%, respectively (P<.01), and the OS rate was 95% versus 75%, respectively (P<.01). Among patients with pCR, no difference was seen in OS irrespective of baseline clinical stage (P=.6), but among patients with residual disease after NAC, a significant difference in OS based on baseline clinical stage was observed (P<.001). Conclusions: Our results suggest pCR after NAC is strongly associated with significantly improved DFS and OS in young women with breast cancer, and perhaps even more so than baseline stage. However, the significantly higher mortality for patients who did not attain pCR highlights the need for better therapies, and the neoadjuvant trial design could potentially serve as an efficient method for rapid triage and escalation/de-escalation of therapies to improve outcomes for young women with breast cancer.
More T Cells versus Better T Cells in Patients with Breast Cancer
Authors: Daniel E. Speiser, Grégory Verdeil
Journal: Cancer Discovery (2017)

Abstract Summary: Characterization of intratumoral leukocyte populations may help in estimating patients' prognosis and predictions. A new study shows remarkable differences between the in situ and invasive breast cancer stages and highlights that cell number analyses should be complemented with characterization of T-cell functions, increasing the likelihood that immune competent antitumor T cells and further biomarkers are identified for guiding therapy choices. Cancer Discov; 7(10); 1062–4. ©2017 AACR. See related article by Gil Del Alcazar et al., p. 1098.
CQC is urged to speed up publication of inspection reports
Authors: Anne Gulland
Journal: BMJ (2017)

Inspectors are taking too long to publish their reports of inspections of health and social care providers in England, the government’s spending watchdog has found.1

In a review of the performance of the Care Quality Commission, the National Audit Office found that delays in publishing inspection reports “mean that information is not provided to the public in a timely way.”

During 2016-17 and the first quarter of 2017-18 the CQC consistently missed its own target for publishing reports, the NAO found. The CQC pledged to publish 90% of reports within 50 days, or 65 days for hospitals with three or more core services. However, in the first quarter of 2017-18 …